摘要
目的:探究重组人Ⅱ型肿瘤坏死因子(TNF)受体-抗体融合蛋白联合风湿骨痛片对类风湿性关节炎(RA)患者的疗效。方法:将90例RA患者随机分为观察组和对照组,每组各45例。对照组给予注射重组人Ⅱ型TNF受体-抗体融合蛋白;观察组注射重组人Ⅱ型TNF受体-抗体融合蛋白联合口服风湿骨痛片。比较两组患者的血清炎症因子、炎性指标、临床疗效、美国健康评估问卷(HAQ)、RA28处关节疾病活动度评分(DAS28)。结果:治疗后,两组患者的IL-6、TNF-α水平比治疗前低,IL-10比治疗前高( P <0.05),观察组的IL-6、TNF-α水平低于对照组,IL-10水平高于对照组( P <0.05);两组患者的类风湿因子(RF)、红细胞沉降率(ESR)、C反应蛋白(CRP)炎性指标均较治疗前更低( P<0.05),且观察组低于对照组(P <0.05);观察组患者临床疗效总有效率为93.33%,高于对照组的73.33%( P <0.05);两组患者HAQ 评分、DAS28及症状积分较治疗前更低( P <0.05),且观察组患者HAQ 评分、DAS28 评分及症状积分低于对照组( P <0.05)。结论:对RA患者采用注射重组人Ⅱ型TNF受体-抗体融合蛋白联合口服风湿骨痛片治疗,提高了临床治疗效果和患者生活质量,减轻了患者的痛苦。
Objective:To explore the therapeutic effect of recombinant human tumor necrosis factor(TNF) receptor type Ⅱ antibody fusion protein combined with Fengshigutong tablet on rheumatoid arthritis(RA) patients.Methods:90 patients with RA were randomly divided into the observation group and the control group,45 cases in each group.The control group was injected with recombinant human type Ⅱ tumor necrosis factor receptor-antibody fusion protein,while the observation group was injected with recombinant human type Ⅱ tumor necrosis factor receptor-antibody fusion protein combined with oral rheumatalgia tablets.The serum inflammatory factors,clinical efficacy,American health assessment questionnaire(HAQ) and RA28 joint disease activity score(DAS28) of the two groups were compared.Results:After treatment,the levels of interleukin-6(IL-6) and TNF-α in the two groups were lower than those before treatment,and the levels of IL-10 were higher than those before treatment(P<0.05).The levels of IL-6 and TNF-α in the observation group were lower than those in the control group,and the levels of IL-10 were higher than those in the control group(P<0.05).The inflammatory indexes of rheumatoid factor(RF),erythrocyte sedimentation rate(ESR) and C-reactive protein(CRP) in the two groups were lower than those before treatment(P<0.05),and those in the observation group were lower than those in the control group(P<0.05).The total effective rate of the observation group was 93.33%,which was higher than that of the control group(73.33%,P<0.05).The HAQ score,DAS28 and symptom score of the two groups were lower than those before treatment(P<0.05),and the HAQ score,DAS28 score and symptom score of the observation group were lower than those of the control group(P<0.05).Conclusion:Injection of recombinant human TNF receptor type Ⅱ antibody fusion protein combined with oral administration of Fengshigutong tablets for RA patients improves the clinical therapeutic effect,greatly reduces the pain of patients and improves the quality of life
作者
刘洪波
靖春颖
韩平
LIU Hong-bo;JING Chun-ying;HAN Ping(Department of Traditional Chinese Medicine,the First Affiliated Hospital of Hainan Medical University;College of Traditional Chinese Medicine,Hainan Medical University,Haikou 571199,Hainan,China)
出处
《川北医学院学报》
CAS
2019年第4期358-361,376,共5页
Journal of North Sichuan Medical College
基金
国家中医药管理局第六批全国老中医药专家学术经验继承项目(2017-29号)
关键词
重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白
风湿骨痛片
类风湿
关节炎
血清炎症因子
临床疗效
Recombinant human type Ⅱ tumor necrosis factor receptor-antibody fusion protein
Fengshigutong tablet
Rheumatoid disease
Arthritis
Serum inflammatory factors
Clinical efficacy
